



WELCURE DRUGS & PHARMACEUTICALS LTD.

Regd. Off.: 33/36 Basement (Back side), West Patel Nagar near Ram Jass Ground, Delhi-110008.
CIN: L24232DL1996PLC227773

Date- 14.02.2023

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code:524661—Welcure Drugs & Pharmaceuticals Limited

Sub: Outcome of Board of Directors Meeting- 14thFebruary, 2023

Respected Sir,

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Board of Directors of the Company in their meeting held today i.e. Tuesday, 14thFebruary, 2023 at 03:30 pm and concluded at 05:30 pm *inter-alia*, approved the following:

- a. Un-Audited Financial Results for the Quarter ended December 31, 2022 along with Limited Review Report.
- b. Request received on 16th January, 2023 from Mr. Dharam Chand Jain, promoter of the company, seeking reclassification of its name from "Promoter and Promoter Group" category to the "Public" category.

Please find enclosed therewith the copies of the following:

1. Un- audited Financial Results of the Company for the quarter ended 31st December, 2022.
2. Auditor's Limited Review Report on the Un-audited Financial Results of the Company for the quarter ended 31st December,2022.

This is for your information and records.

Thanking you



WELCURE DRUGS & PHARMACEUTICALS LTD.

Regd. Off.: 33/36 Basement (Back side), West Patel Nagar near Ram Jass Ground, Delhi-110008.
CIN: L24232DL1996PLC227773

For Welcure Drugs & Pharmaceuticals Limited

WBhal
Name: Vishal Mehra

DIN: 09717741

Designation: Managing Director

Address: 47, RadheyPuriExtn 2, Gali
No.4, Krishna Nagar, East Delhi,
Delhi-110051



WELCURE DRUGS AND PHARMACEUTICALS LIMITED
CIN: L24232DL1996PLC227773
Registered Office: 33/36 Basement (Back side), West Patel Nagar near Ram Jass Ground, West Delhi, Delhi - 110008
Un-Audited Financial Results for Quarter & Nine Month Ended 31st December 2022

(Amount in Lakhs)

S. No.	Particulars	Quarter Ended			Nine Month ended		Previous year ended
		31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
I	Income						
	a) Revenue from Operations	0.00	0.00	0.00	0.00	0.00	0.00
	b) Other Operating Income	0.00	0.00	0.00	0.00	2.25	10.50
II	Other Income	0.69	0.90	0.00	1.59	0.00	0.00
III	Total Income from operations (net)	0.69	0.90	0.00	1.59	2.25	10.50
IV	Expenses						
	Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, work in progress and stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee Benefit expenses	0.35	0.36	0.36	0.71	0.93	1.29
	Finance costs	0.00	0.00	0.00	0.00	0.00	0.00
	Depreciation and amortisation expenses	0.00	0.00	0.00	0.00	0.00	0.00
	Other Expenses	0.59	1.17	0.22	1.76	5.65	4.85
	Total Expenses (IV)	0.94	1.53	0.58	2.47	6.58	6.14
V	Profit/(Loss) before exceptional items (I-IV)	-0.24	-0.63	-0.58	-0.87	-4.33	2.36
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/(Loss) before extraordinary items and tax (v-vi)	0.00	0.00	0.00	0.00	0.00	0.00
VIII	Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit/(Loss) before tax (VII-VIII)	-0.24	-0.63	-0.58	-0.87	-4.33	2.36
X	Tax Expenses						
	(i) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
XI	Profit/(Loss) for the period from continuing operations (IX-X)	-0.24	-0.63	-0.58	-0.87	-4.33	2.36
XII	Net Profit/(Loss) for the period from discontinuing operations (before tax)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Tax expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XIV	Net Profit/(Loss) for the period from discontinued operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00	0.00
XV	Net Profit/(Loss) for the period (XI+XIV)	-0.24	-0.63	-0.58	-0.87	-4.33	2.36
XVI	Share of profit / (loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00
XVII	Share of profit / (loss) of minority	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates	-0.24	-0.63	-0.58	-0.87	-4.33	2.36
XIX	Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00
XX	Total Comprehensive Income for the period (XVIII-XIX)	-0.24	-0.63	-0.58	-0.87	-4.33	2.36
XXI	Paid up share capital (Face Value of Rs. 10/- per share)	1,343.91	1,343.91	1,211.86	1,343.91	1,211.86	1,211.86
XXII	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00	1,202.58
XXIII	Earning per Equity Share (for continuing operations):						
	(1) Basic	0.000	0.000	0.000	-0.001	-0.004	0.002
	(2) Diluted	0.000	0.000	0.000	-0.001	-0.004	0.002

NOTES:

- The Statement of Unaudited Financial results for the Quarter & Nine months ended December 31, 2022 have been reviewed by the audit committee and approved by the Board of directors at their respective meetings held on October 14, 2022. There are no qualifications in Limited Review Report issued by the auditor.
- The financial results for the quarter and nine months ended December 31, 2022 have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- There were no investor complaints pending during the Quarter ended December 31, 2022.
- As the Company is mainly operating in one reportable business segment, hence the disclosure requirements of Indian Accounting Standard (Ind AS-108) "Operating Segment" is not applicable.
- The Previous Quarter ended figures have been re-grouped/ re-arranged, whenever necessary.
- There is no need to provide any reconciliation as required by the circular dated July 05, 2016, since there is no change in the figures due to transit from the previous Indian GAAP to Ind-AS.

For WELCURE DRUGS AND PHARMACEUTICALS LIMITED

Vishal
Mehta

Director
DIN: 09731743

Date: 14/01/2023
Place: Delhi





V.P. Gupta & Co.

Chartered Accountants

LIMITED REVIEW REPORT

(For the Quarter & Nine months ended on December 31, 2022)

To
The Board of Directors,
Welcure Drugs & Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Welcure Drugs & Pharmaceuticals Limited ("the Company") for the Quarter & Nine months ended December 31, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("the Regulations") as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular")
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors on 14th February, 2023 has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind-AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditors of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies



288, Ghalib Apartments, Parwana Road, Pitampura, Delhi 110034, India

Ph. :- 91-11-27020321, 9313675636 Email:- tax@vpguptaandco.com



V.P. Gupta & Co.

Chartered Accountants

5. Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, that has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements

Place: Delhi
Date: 14.02.2023

For V.P. Gupta & Co.
Chartered Accountants

FRN: 000699N



CA V.P. Gupta
Partner

M No.: 080557

UDIN: 23080557BGYZIJ5402

288, Ghalib Apartments, Parwana Road, Pitampura, Delhi 110034, India

Ph. :- 91-11-27020321, 9313675636 Email:- tax@vp Gupta and co, com